PLoS ONE · 2011 · 88 citations · 32 references
Life SciencesImmunologyInfectious DiseasesHost-pathogen InteractionsInnate ImmunityVirologyAntiviral ImmunityHost-virus InteractionsInnate Immune ResponseInterferon ResponsesToll-like ReceptorsViral InfectionsAntiviral Interferon ResponsesInhibition Of Interferon ResponsesInnate Immunity PathwaysToll-like Receptor LigandsToll-like Receptor SignalingToll-like Receptor Signaling PathwaysToll-like Receptor-mediated Innate Immune ResponseVirus Replication Inhibition
Toll-like receptors (TLRs) play an important role in innate immunity against invading pathogens. Although TLR signaling has been indicated to protect cells from infection of several viruses, the role of TLRs in Dengue virus (DENV) replication is still unclear. In the present study, we examined the replication of DENV serotype 2 (DENV2) by challenging hepatoma cells HepG2 with different TLR ligands. Activation of TLR3 showed an antiviral effect, while pretreatment of other TLR ligands (including TLR1/2, TLR2/6, TLR4, TLR5 or TLR7/8) did not show a significant effect. TLR3 ligand poly(I:C) treatment prior to viral infection or simultaneously, but not post-treatment, significantly down-regulated virus replication. Pretreatment with poly(I:C) reduced viral mRNA expression and viral staining positive cells, accompanying an induction of the type I interferon (IFN-β) and type III IFN (IL-28A/B). Intriguingly, neutralization of IFN-β alone successfully restored the poly(I:C)-inhibited replication of DENV2. The poly(I:C)-mediated effects, including IFN induction and DENV2 suppression, were significantly reversed by IKK inhibitor, further suggesting that IFN-β is the dominant factor involved in the poly(I:C) mediated antiviral effect. Our study presented the first evidence to show that activation of TLR3 is effective in blocking DENV2 replication via IFN-β, providing an experimental clue that poly(I:C) may be a promising immunomodulatory agent against DENV infection and might be applicable for clinical prevention.
32
IL-28, IL-29 and their class II cytokine receptor IL-28R
Paul O. Sheppard, Wayne Kindsvogel, Wenfeng Xu et al. · Nature Immunology · 2002 · 1.6K citations
Nina Ank, Hans West, Christina Bartholdy et al. · Journal of Virology · 2006 · 596 citations · Full text